Clinical trials: Aromatase Inhibitor
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
This phase IIA trial studies the side effects of ribociclib and aromatase inhibitor and how well they work in treating participants with hormone receptor positive breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT03477396
- Testing
- Aromatase Inhibitor, Laboratory Biomarker Analysis, Pharmacokinetic Study
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Endometrial Cancer
Endometrial Changes in Breast Cancer Women With or Without Hormonal Therapies
A history of breast cancer is a risk factor for the development of endometrial pathologies, such as typical and atypical glandular hyperplasia, endometrial polyps, uterine fibroids, endometrial adenocarcinoma and uterine sarcoma…
- Trial name
- BETA-1 (NCT03898947)
- Testing
- Diagnostic hysteroscopy and targeted endometrial biopsy
- Volunteers
- 1,329 people
- Sponsor
- Università degli Studi dell'Insubria
Aromatase Inhibitor, Musculoskeletal Symptoms
Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings
Aromatase inhibitor therapy has become a standard adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer.
- Conditions
- Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors
- Trial name
- NCT03697200
- Testing
- APA, Education control
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Johns Hopkins University
Short Stature
Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole
The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole…
- Trial name
- NCT02137538
- Testing
- Letrozole, Anastrozole
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Stanford University
Breast Cancer
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D…
- Trial name
- VITAL (NCT00867217)
- Testing
- High Dose Vitamin D, Standard Dose Vitamin D3, Letrozole 2.5mg
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- Qamar Khan
Breast Cancer
Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.
Despite advances in early detection and treatment strategy, about 25 to 40% of patients treated for breast cancer develop metastasis. Some patients are in a therapeutic impasse situation.
- Trial name
- EFESE (NCT02866955)
- Testing
- Estramustine, Tamoxifen
- Where
- 21 sites in France
- Volunteers
- 100 people
- Sponsor
- Institut de Cancérologie de Lorraine
Advanced Metastatic Breast Cancer
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
The purpose of this study was to determine whether treatment with tamoxifen or a non-steroidal aromatase inhibitors (NSAI) + goserelin + LEE011 prolonged progression-free survival (PFS) compared to treatment with tamoxifen or a…
- Trial name
- MONALEESA-7 (NCT02278120)
- Testing
- Ribociclib, Tamoxifen, Letrozole
- Where
- 183 sites in United States, Argentina and 28 more
- Volunteers
- 672 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Initiation and Maintenance Disorders, Pain
Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients
Many women with breast cancer who are treated with aromatase inhibitor medications develop difficulty sleeping and fatigue during treatment.
- Trial name
- NCT01921296
- Testing
- Cyclobenzaprine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Lynn Henry
Aromatase Inhibitor-Associated Musculoskeletal Syndrome, Arthralgia Syndrome
AKU Study - Acupuncture for Aromatase Inhibitor-Induced Musculoskeletal Syndrome
Third-generation aromatase inhibitors (AIs) represent a standard adjuvant endocrine treatment for postmenopausal and high-risk premenopausal women with hormone receptor-positive early breast cancer.
- Conditions
- Aromatase Inhibitor-Associated Musculoskeletal Syndrome, Arthralgia Syndrome, Early Breast Cancer (EBC)
- Trial name
- AKU (NCT07909785)
- Testing
- Manual Acupuncture
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- Masaryk Memorial Cancer Institute